ESSEX

ESSEX Bio-Technology Limited is a biopharmaceutical company that focuses on the research, development, production, and sales of genetically engineered drugs such as rb-bFGF (recombinant bovine basic fibroblast growth factor, also known as FGF-2). Since 1998, six genetically engineered new drugs have been launched in China. Additionally, the company offers a range of preservative-free single-dose eye drops and products like the Shili Shun® Lecithin Complex Iodine Capsules. The company's products are primarily used for wound healing and disease treatment in ophthalmology and dermatology prescription medications. Currently, with 43 sales and promotion offices in major Chinese cities, the company has successfully covered more than 10,500 hospitals across China. Leveraging its internal R&D platform based on growth factors and antibodies, the company possesses a pipeline of various products at different clinical stages, addressing a wide range of therapeutic areas.